Drugs / high-titer anti-Sars-CoV-2 plasma
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04333251 | Apr 2020 → Sep 2021 | pneumonia | Baylor Research Institute | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | high-titer anti-Sars-CoV-2 plasma | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04333251 ↗ |
| Known as | Human convalescent plasma | “Human convalescent plasma is an option for COVID-19 treatment and could be available from people who have recovered and can donate plasma.” NCT04333251 ↗ |
| Modality | Protein / enzyme biologic | “convalescent plasma contains neutralizing antibodies to the relevant virus.” NCT04333251 ↗ |